Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "score"

814 News Found

AbbVie’s Atogepant shows breakthrough results for acute migraine relief
Clinical Trials | December 03, 2025

AbbVie’s Atogepant shows breakthrough results for acute migraine relief

Suffering from acute migraine? You may soon bid adieu to the debilitating headache


Belite Bio reports landmark phase 3 success for Stargardt Disease therapy
Clinical Trials | December 03, 2025

Belite Bio reports landmark phase 3 success for Stargardt Disease therapy

Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging


Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval
News | December 03, 2025

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection


FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
Drug Approval | December 02, 2025

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA


Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
Clinical Trials | December 02, 2025

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM


Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
News | December 02, 2025

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month


Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
News | December 01, 2025

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials


Roche expands Veeva partnership with global rollout of AI-driven Vault CRM
Digitisation | December 01, 2025

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

Roche says the move marks a step forward in its digital transformation strategy


Sudapack breaks ground on major PharmaGuard expansion in Erolzheim
Supply Chain | December 01, 2025

Sudapack breaks ground on major PharmaGuard expansion in Erolzheim

Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production